Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Athanasios G Papatsoris

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
Expert Opinion on Investigational Drugs|March 9, 2016
Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancerAthanasios Dellis, Athanasios G Papatsoris
Urological Research|November 19, 2009
Status quo of percutaneous nephrolithotomy in childrenSotirios Bogris, Athanasios G Papatsoris
Journal of Endourology|September 15, 2009
Diagnosis and management of postpercutaneous nephrolithotomy residual stone fragmentsAndreas Skolarikos, Athanasios G Papatsoris
Postgraduate Medical Journal|March 7, 2008
Men's behaviour towards prostate cancer screeningAthanasios G Papatsoris, Fotios Anagnostopoulos
Expert Opinion on Investigational Drugs|April 23, 2014
Intravesical treatment of bladder pain syndrome/interstitial cystitis: from the conventional regimens to the novel botulinum toxin injectionsAthanasios Dellis, Athanasios G Papatsoris
Expert Review of Pharmacoeconomics & Outcomes Research|February 26, 2014
The economics of abiraterone acetate for castration-resistant prostate cancerAthanasios Dellis, Athanasios G Papatsoris
Expert Opinion on Biological Therapy|October 1, 2013
Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancerAthanasios Dellis, Athanasios G Papatsoris
Journal of Endourology|January 29, 2010
A novel thermo-expandable ureteral metal stent for the minimally invasive management of ureteral stricturesAthanasios G Papatsoris, Noor Buchholz
Angiology|January 31, 2006
Hypertension, antihypertensive therapy, and erectile dysfunctionAthanasios G Papatsoris, Panagiotis G Korantzopoulos
Expert Opinion on Pharmacotherapy|November 22, 2018
Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancerAthanasios E Dellis, Athanasios G Papatsoris
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
Expert Opinion on Investigational Drugs|March 9, 2016
Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancerAthanasios Dellis, Athanasios G Papatsoris
Urological Research|November 19, 2009
Status quo of percutaneous nephrolithotomy in childrenSotirios Bogris, Athanasios G Papatsoris
Journal of Endourology|September 15, 2009
Diagnosis and management of postpercutaneous nephrolithotomy residual stone fragmentsAndreas Skolarikos, Athanasios G Papatsoris
Postgraduate Medical Journal|March 7, 2008
Men's behaviour towards prostate cancer screeningAthanasios G Papatsoris, Fotios Anagnostopoulos
Expert Opinion on Investigational Drugs|April 23, 2014
Intravesical treatment of bladder pain syndrome/interstitial cystitis: from the conventional regimens to the novel botulinum toxin injectionsAthanasios Dellis, Athanasios G Papatsoris
Expert Review of Pharmacoeconomics & Outcomes Research|February 26, 2014
The economics of abiraterone acetate for castration-resistant prostate cancerAthanasios Dellis, Athanasios G Papatsoris
Expert Opinion on Biological Therapy|October 1, 2013
Denosumab as a promising novel bone-targeted agent in castration resistant prostate cancerAthanasios Dellis, Athanasios G Papatsoris
Journal of Endourology|January 29, 2010
A novel thermo-expandable ureteral metal stent for the minimally invasive management of ureteral stricturesAthanasios G Papatsoris, Noor Buchholz
Angiology|January 31, 2006
Hypertension, antihypertensive therapy, and erectile dysfunctionAthanasios G Papatsoris, Panagiotis G Korantzopoulos
Expert Opinion on Pharmacotherapy|November 22, 2018
Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancerAthanasios E Dellis, Athanasios G Papatsoris
Pageof 10